References in periodicals archive ?
The left ventricular assist device market (LVAD) companies compete with each other on the basis of substantially greater or broader financial base of the company, product development, sales and marketing resources and experience.
Perioperative considerations in the patient with a left ventricular assist device.
WASHINGTON -- Patients with left ventricular assist devices who undergo surgery that is unrelated to their device can safely manage the operation without device complications, according to results achieved at a single center.
com), manufacturer of the HeartAssist 5[TM] left ventricular assist device (LVAD), announced that Ash Attia has joined the company as Vice President of Asia-Pacific.
Table 17: Heartmate II (DT) - Initial clinical experience with the HeartMate II axial-flow left ventricular assist device.
On November 27, 2013, after the market closed, The New England Journal of Medicine released a study entitled, "Unexpected Abrupt Increase in Left Ventricular Assist Device Thrombosis" concluding that the "rate of pump thrombosis related to the use of the HeartMate II has been increasing at our centers and is associated with substantial morbidity and mortality.
Garry Davis, a 42-year-old oilrig worker who suffered from a rare blood disease, which damaged his organs, received a heart and liver transplant after being kept alive on a left ventricular assist device (LVAD) for two months.
NEW ORLEANS -- A left ventricular assist device permits myocardial recovery sufficient for device explantation without heart transplantation in a disappointingly small fraction of patients with chronic heart failure, according to the first prospective study to examine this issue.
Thoratec Accused of Failing to Disclose Risks Associated with HeartMate II Left Ventricular Assist Device
I'm concerned that some patients may receive an ICD who don't meet these criteria, and who may be better served by some other treatment such as a left ventricular assist device or heart transplantation.
Medicare patients who are suffering from chronic end-stage heart failure but are not candidates for a heart transplant will soon be eligible to receive part of the cost of a left ventricular assist device (LVAD).

Full browser ?